Core Insights - Hims & Hers (HIMS) is expanding its Weight Loss Program to the United Kingdom, launching the Hers platform to provide holistic weight management care to eligible women [1][7] Expansion and Growth - The weight-loss programs in the United States have been a significant growth driver for Hims & Hers in 2025, leading to rapid subscriber and revenue growth, supported by strong clinical outcomes and adherence metrics [2] - Following the success in the U.S., the company is focusing on international expansion, having already launched in Canada earlier this year and acquired the European telehealth platform Zava, which provides access to markets in Germany, France, and Ireland [2] Market Potential - The international expansion into the U.K. is part of a broader strategy to tap into lucrative markets, with 64% of adults in the U.K. classified as overweight or living with obesity, indicating a substantial target patient population [4] - Despite the high prevalence of obesity, access to advanced obesity treatments, such as GLP-1 drugs, remains limited in the U.K., creating an opportunity for Hims & Hers to provide seamless access to its Weight Loss Program [5] Service Offerings - The Hers platform will offer eligible customers transparent pricing and personalized weight management programs, guided by GMC-registered doctors after a thorough intake assessment [8] - The platform will include treatment options like branded GLP-1 drugs (e.g., Mounjaro, Wegovy) and non-prescription treatments (e.g., Orlos), along with comprehensive support including 24/7 care team access and resources for improving nutrition, movement, and sleep habits [9]

Core Insights - Hims & Hers is expanding its Weight Loss Programme in the UK, introducing the Hers platform to provide comprehensive weight management care for women [1][5] - The initiative addresses the high prevalence of obesity in the UK, where 64% of adults are overweight or living with obesity, and aims to remove barriers to access GLP-1 treatment plans [2][5] Group 1: Programme Details - The Weight Loss Programme includes personalized treatment plans designed by GMC-registered doctors, offering options like GLP-1 medications (Mounjaro, Wegovy) and non-prescription treatments (Orlos) [3] - Customers receive ongoing support from licensed clinicians, including 24/7 access to care teams and resources to improve nutrition, movement, and sleep habits [3][4] Group 2: Market Commitment - The launch of the Hers platform signifies a commitment to providing accessible, evidence-based, and sustainable weight management care, complementing the NHS [5] - The company aims to address the global obesity epidemic by prioritizing long-term health solutions over quick fixes, ensuring women have access to dedicated care [5] Group 3: Future Plans - Hims & Hers plans to continue expanding its offerings in response to growing demand for personalized care in the UK [5]